【摘要】 目的观察恩度联合多西紫杉醇治疗小细胞肺癌的疗效及安全性。方法选取NSCLC患者79例,随机分为观察组41例,对照组38例,观察组于d1、d8静脉滴注多西紫杉醇30mg/m2;d1～d14静点恩度15mg。对照组患者仅应用多西紫杉醇。依照RECIST标准疗效分为:完全缓解、部分缓解、无进展、恶化。客观有效率=完全缓解+部分缓解;临床受益率=完全缓解+部分缓解+无进展。不良反应按照NCICTC3.0分为0～4度。结果客观有效率:观察组68.3%,对照组31.6%;临床受益率:观察组90.2%,对照组50.0%。差异有统计学意义,P<0.05。不良反应组间比较,无统计学意义。结论恩度联合多西紫杉醇治疗NSCLC疗效显著,安全性较高,具有临床应用价值。更多还原

【Abstract】 Objective To observe the efficacy of Endostar(recombinant human endostatin)combined with docetaxel in the treatment of small cell lung cancer and its safety.Methods 79 patients with NSCLC,were randomly divided into the observation group 41 cases,38 cases of the control group,the observation group in D1,D8 intravenous infusion of docetaxel in 30mg/m2;D1 ～D14 15mg static point temperature.Patients in the control group only by docetaxel.In accordance with the RECIST standard efficacy is divided into: complete remission,partial remission,no progress,deterioration.Objective efficiency=complete remission+partial remission;clinical benefit rate=complete remission+partial remission+no progress.Adverse reactions to NCICTC3.0 divided into 0～4 degrees.Results Objective efficiency: the observation group 68.3%,contrast group 31.6%;clinical benefit rate: the observation group 90.2%,contrast group 50%.The differences were statistically significant,P<0.05.Adverse reactions were compared between groups,no statistical significance.Conclusion Combined with docetaxel in the treatment of NSCLC has obvious curative effect,high safety,has the value in clinical application.更多还原